Media 280723

CTO Mr Craig Weller said on Aqua Phase studies revealing the absorption of CBD as more than 4 times greater than CBD in oil:
Bod has been sweating on the PK study for months. It needed to show improved bioavailability of 30% for the deal to proceed, it exceeded by a factor of 10, what this means is that if we ingest 100mg of CBD in oil, we will normally absorb 6-8% of the dose. With Aqua Phase, the CBD absorption is 32% This means we can either get a better response to the CBD or otherwise we can reduce the Aqua Phase dose – giving potentially less side effects and providing CBD raw material savings.
Bod plotting ‘immediate’ overseas move if CBD sleep trial succeeds
19 Jul 2023
Published by: Cannabiz
Bod Completes Trial Of Schedule 3 Cannabidiol Contender
13 Jul 2023
Published by: Hemp Gazette
How Bod Science pulled ahead in the race for Australia’s first over-the-counter CBD
13 Jul 2023
Published by: Stockhead
Bod Science Limited (ASX:BOD) Investor Presentation | July 2023
13 Jul 2023
Published by: Bod Science
Bod Science faces nervy wait as final patient completes S3 clinical trial
10 Jul 2023
Published by: Cannabiz
ASX Health Stocks: Bod Science provides ‘landmark update’, while Incannex prepares to list on Nasdaq
10 Jul 2023
Published by: Stockhead
Microcap Cannabis Stock BOD has two major near term catalysts…
26 Jun 2023
Published by: Next Investors
Australia’s Bod Inks Malaysian Medical Cannabis LOI
23 Jun 2023
Published by: Hemp Gazette